The XKRY2 inhibitors represent a class of chemical entities dedicated to modulating the activity or expression of the XKRY2 protein, which is known to be a Y-linked gene with specific roles in mammalian cells. As the precise physiological function of XKRY2 is still under extensive study, these inhibitors have piqued the interest of researchers aiming to elucidate the broader roles of Y-linked genes in cellular processes. By inhibiting XKRY2, these chemical agents grant scientists a tool to discern the direct and indirect contributions of this protein to cellular events and phenotypes. While the exact modes of action of these inhibitors may vary, they generally aim to reduce the expression or activity of XKRY2 either at the transcriptional, post-transcriptional, or protein-functional level.
Molecules that belong to the XKRY2 inhibitor class could operate through a myriad of mechanisms. Some might bind directly to the XKRY2 protein, altering its conformation and consequently, its function. Others could influence the upstream regulatory pathways that dictate the expression of the XKRY2 gene, resulting in lowered transcript levels. Additionally, post-transcriptional regulators could hinder the translation of XKRY2 mRNA or expedite the degradation of the XKRY2 protein. The diversity in potential mechanisms emphasizes the versatility of this chemical class. As research progresses, the refinement and categorization of XKRY2 inhibitors, based on their specific modes of action, will be pivotal in harnessing their full potential for scientific exploration.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
By causing DNA breaks via topoisomerase II inhibition, etoposide could disrupt the accessibility or transcriptional integrity of the XKRY2 gene. | ||||||
Teniposide | 29767-20-2 | sc-204910 sc-204910A | 25 mg 100 mg | $73.00 $235.00 | 6 | |
Similar to etoposide, teniposide might interfere with XKRY2 gene transcription by inducing DNA damage. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
As a pyrimidine analog, 5-FU may incorporate into the XKRY2 transcript, potentially leading to faulty RNA processing or degradation. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
By limiting thymidine production, methotrexate could indirectly hinder the replication and transcription of the XKRY2 gene. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
If XKRY2 expression is modulated by certain kinases, genistein might inhibit those pathways and thereby reduce XKRY2 transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
If XKRY2 is regulated via PI3K-dependent pathways, LY294002 could suppress its transcription by inhibiting PI3K. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
By inhibiting various protein kinases, staurosporine could alter signaling pathways that modulate XKRY2 transcription. | ||||||
Zebularine | 3690-10-6 | sc-203315 sc-203315A sc-203315B | 10 mg 25 mg 100 mg | $129.00 $284.00 $1004.00 | 3 | |
Zebularine might modify the methylation state around the XKRY2 locus, possibly leading to altered gene transcription. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor; if XKRY2's expression is PI3K-dependent, wortmannin might hinder its transcription. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
If XKRY2 transcription is influenced by EGFR signaling, AZD9291 could impact its expression through EGFR pathway inhibition. | ||||||